二甲双胍使用对动脉瘤性蛛网膜下腔出血结局的影响
这项单中心回顾性研究纳入2009至2023年900例动脉瘤性蛛网膜下腔出血患者,按入院前是否使用二甲双胍分为47例与853例两组。二甲双胍组与非二甲双胍组的迟发性脑缺血发生率相似(38.3% vs 29.3%,aOR=1.06 [0.49-2.28]),校正后7天血管造影脑血管痉挛在敏感性分析中较低(aOR=0.44 [0.20-0.98]),再出血与院内死亡率组间相似。
要点
- 二甲双胍组与非二甲双胍组迟发性脑缺血发生率相似(38.3% vs 29.3%,aOR=1.06 [0.49-2.28])。
- 排除舒适照护患者后,二甲双胍组7天血管造影脑血管痉挛较低(aOR=0.44 [0.20-0.98])。
- 再出血与院内死亡率组间相似,结论需更大规模多机构数据进一步研究。
核心结论
- 动脉瘤性蛛网膜下腔出血前使用二甲双胍未显著影响迟发性脑缺血或脑血管痉挛风险。
- 排除舒适照护患者后,结果高度提示蛛网膜下腔出血后7天脑血管痉挛风险降低。
- 再出血与死亡率在各组间相似。
- 需要更大规模、多机构数据集进一步研究二甲双胍的影响,尤其是在蛛网膜下腔出血期间及之后。
研究设计与样本
- 单中心回顾性综述,评估2009年至2023年动脉瘤性蛛网膜下腔出血患者。
- 按入院前是否使用二甲双胍分组,共纳入900例患者(二甲双胍组47例,非二甲双胍组853例)。
- 主要结局为迟发性脑缺血,次要结局包括院内死亡、再出血、血管造影脑血管痉挛以及出院时和3个月随访时改良Rankin量表评分良好。
- 采用逻辑回归分析结局,排除接受舒适照护的患者后进行敏感性分析。
主要发现
- 迟发性脑缺血发生率组间相似:二甲双胍组38.3% vs 非二甲双胍组29.3%,aOR=1.06 [0.49-2.28]。
- 再出血率:二甲双胍组4.3% vs 非二甲双胍组5.6%,aOR=0.47 [0.09-2.51]。
- 院内死亡率:二甲双胍组4.3% vs 非二甲双胍组9.7%,aOR=0.47 [0.08-2.84]。
- 血管造影脑血管痉挛:二甲双胍组38.3% vs 非二甲双胍组52.8%,aOR=0.49 [0.23-1.05];7天时分别为29.8% vs 47.6%,aOR=0.46 [0.21-1.01]。
- 敏感性分析显示迟发性脑缺血发生率相似(39.1% vs 30.9%,aOR=0.98 [0.45-2.15]),但二甲双胍组7天脑血管痉挛较低(aOR=0.44 [0.20-0.98])。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metformin is widely prescribed and has neuroprotective effects in animals, but its impact on brain injury after aneurysmal subarachnoid hemorrhage (aSAH) in humans is unclear. METHODS: This single-center retrospective review assessed patients with aSAH from 2009 to 2023, categorizing them based on pre-admission metformin use. The primary outcome was delayed cerebral ischemia (DCI), while secondary outcomes included in-hospital mortality, rebleeding, angiographic cerebral vasospasm (CVS), and favorable modified Rankin Scale (mRS) scores at discharge and the 3-month follow-up. Outcomes were analyzed using logistic regression. Sensitivity analysis was performed after excluding patients receiving comfort care. RESULTS: A total of 900 patients were included (47 metformin and 853 non-metformin). DCI rates were similar between groups (38.3% vs. 29.3%, aOR = 1.06 [0.49-2.28]). Rebleeding rates were 4.3% for metformin users and 5.6% for non-users (aOR = 0.47 [0.09-2.51]). In-hospital mortality was 4.3% in metformin users vs. 9.7% in non-users (aOR = 0.47 [0.08-2.84]). Angiographic CVS was 38.3% in metformin users and 52.8% in non-users (aOR = 0.49 [0.23-1.05]), and at 7 days, CVS was 29.8% vs. 47.6% (aOR = 0.46 [0.21-1.01]). Sensitivity analysis showed similar DCI rates (39.1% vs. 30.9%, aOR = 0.98 [0.45-2.15]) but lower CVS at 7 days for metformin users (aOR = 0.44 [0.20-0.98]). CONCLUSION: Metformin use before aSAH did not significantly affect the risk of DCI or CVS. However, after excluding comfort care patients, the findings are highly speculative of reduced CVS risk at 7 days post-aSAH. Rebleeding and mortality rates were similar across groups. Future research with larger, multi-institutional datasets is needed to better understand metformin's impact, particularly during and after aSAH.
引用
- Bueno A, Becerril-Gaitan A, Mokua C, et al. Effects of metformin use on aneurysmal subarachnoid hemorrhage outcomes. Acta Neurochir (Wien). 2025. PMID: 40208362. doi:10.1007/s00701-025-06516-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。